Article ; Online: Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials.
Alzheimer's & dementia : the journal of the Alzheimer's Association
2024 Volume 20, Issue 4, Page(s) 3119–3125
Abstract: Introduction: Adverse effects of monoclonal antibodies against amyloid beta are common, and may affect validity of randomized controlled trials (RCTs) through unblinding of participants.: Methods: We used observations from published phase 3 RCTs in ... ...
Abstract | Introduction: Adverse effects of monoclonal antibodies against amyloid beta are common, and may affect validity of randomized controlled trials (RCTs) through unblinding of participants. Methods: We used observations from published phase 3 RCTs in Alzheimer's disease to calculate the magnitude of unblinding effects on cognition that would be required to explain observed cognitive benefits in RCTs. Results: In trials of lecanemab, aducanumab, and donanemab, incidence of amyloid-related imaging abnormalities with active treatment ranged from 22% to 44%, the vast majority of which presumably led to unblinding. Effects of unblinding on the Clinical Dementia Rating Sum of Boxes required to fully explain observed drug effects ranged from 1.1 point (95% confidence interval: 0.2-2.0) with aducanumab, to 3.3 points (2.1-4.4) with donanemab and 3.7 points (2.0-5.6) with lecanemab. Infusion-related reactions were common, with potential unblinding effects particularly for lecanemab. Similar patterns were observed for the Alzheimer's Disease Assessment Scale Cognitive subscale. Discussion: Psychological treatment effects due to unblinding may explain a substantial share of observed treatment effects in RCTs. |
---|---|
MeSH term(s) | Humans ; Alzheimer Disease/drug therapy ; Amyloid beta-Peptides ; Amyloidogenic Proteins ; Cognition ; Drug-Related Side Effects and Adverse Reactions ; Antibodies, Monoclonal, Humanized |
Chemical Substances | donanemab ; Amyloid beta-Peptides ; Amyloidogenic Proteins ; Antibodies, Monoclonal, Humanized |
Language | English |
Publishing date | 2024-02-21 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 2211627-8 |
ISSN | 1552-5279 ; 1552-5260 |
ISSN (online) | 1552-5279 |
ISSN | 1552-5260 |
DOI | 10.1002/alz.13690 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6316: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 540: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.